Published on : Jul 13, 2017
Albany, New York, July 13, 2017: As per the findings of a recent study, over 2.8 million people are infected yearly with Chlamydia all USA, it has become the most prevalent sexually transmitted diseases in the world. However, if left untreated, it can become pelvic inflammatory disease (PID), which is a major cause of infertility, ectopic pregnancy and chronic pelvic pain. Considering this fact, several doctors are increasing their focus on treatment of sexually transmitted diseases globally, which as a result bolstering the Chlamydia Infection market growth. Market Research Hub (MRH) has lately announced the inclusion of a new study to its vast archive, which is titled as “Chlamydia Infection Diagnostics and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025”. This 211 pages study analyzes the current and future prospects of the market by covering major regions.
It has been analyzed that Chlamydial infection, caused by Chlamydia trachomatis, is the most frequently reported infectious disease in the United States, and prevalence is highest in persons aged ?24 years. Untreated Chlamydia may lead to more serious health problems that are why it is important to get tested as early as possible. At present, the therapeutics used for treatment of chlamydia infection include Macrolides, Quinolones, Sulfonamides, Tetracycline and Aminopenicillins. Macrolides are the antibiotics most commonly prescribed to treat chlamydia infection. Additionally, C. trachomatis can be diagnosed by culture, Nucleic Acid Amplification Tests (NAATs), Direct Fluorescent Tests, and others (ELISAs). As per the key findings, the chlamydia infection diagnostics and therapeutics market will expand at a robust CAGR of 6.0% over the forecast period between 2017 and 2025.
In the first part, the research highlights the market overview of therapeutics market along with industry developments. A detailed qualitative analysis of factors responsible for driving and restraining market growth and opportunities has been provided in the market overview section. In terms of geography, the global chlamydia infection diagnostics and therapeutics market have been segmented into five regions: North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Of these, North America was the largest regional market in terms of revenue in 2016, which is also expected to remain same in the coming years. The prime reasons behind this region’s growth is a well-established health care industry, increasing incidence of chlamydia infection among population, and availability of well-defined reimbursement policies.
Moreover, the market segmentation is based on product type, end-user, diagnosis and region. In terms of product type, the segment of nucleic acid amplification is expected to steadily expand at a moderate CAGR, over the report’s forecast period. Drugs commonly used to treat chlamydia include Amoxil, Doryx, Doxycycline, Erythrocin, Floxin, Gantrisin, Trimox, Zithromax and other. Further, growth rates for each segment within the global chlamydia infection diagnostics and therapeutics market have been determined.
Key companies profiled in the report include DiaSorin SpA, Bio Rad laboratories, Novartis AG, F Hoffmann-La Roche, Danaher, bioMerieux, Siemens AG, Thermo Fisher Scientific, Abbott Laboratories, and Becton Dickinson and Company.
Click here to get more info with TOC in a PDF Format : http://www.marketresearchhub.com/enquiry.php?type=S&repid=1202079
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org